GH · Guardant Health, Inc.
$157.58
-5.60 (-3.43%)
At close · Aug 6
Market Cap
$21.15B
Shares
134.20M
Guardant Health, Inc. Earnings Call Transcripts
Every quarterly earnings call for Guardant Health, Inc. (GH) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲23.9%
$117.40M
−$161.99M
'22 Q3
22-11-03
▲17.4%
$126.89M
−$139.95M
'22 Q4
23-02-23
▲33.9%
$128.71M
−$133.53M
'23 Q1
23-05-09
▲25.7%
$137.15M
−$72.77M
'23 Q2
23-08-03
▲21.8%
$143.03M
−$86.10M
'23 Q3
23-11-06
▲22.2%
$155.05M
−$186.99M
'23 Q4
24-02-22
▲30.9%
$168.49M
−$114.98M
'24 Q1
24-05-09
▲29.2%
$177.24M
−$102.63M
'24 Q2
24-08-07
▲33.9%
$191.48M
−$107.75M
'24 Q3
24-11-06
▲30.2%
$201.81M
−$111.03M
'24 Q4
25-02-20
▲20.8%
$203.47M
−$95.16M
'25 Q1
25-04-30
▲30.9%
$232.09M
−$99.90M
'25 Q2
25-07-30
▲38.5%
$265.20M
−$92.72M
'25 Q3
25-10-29
▲39.4%
$281.27M
−$128.52M
'25 Q4
26-02-19
▲48.3%
$301.67M
−$112.08M
'26 Q1
26-05-07
LATEST
▲44.3%
$334.98M
−$120.14M
'26 Q2
26-07-30
Conference
Investor event
2026-08-12
Canaccord Genuity 46th Annual Growth Conference
Scheduled
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-07-30
Guardant Health Q2 2026 Earnings Call
Confident tone
SHIELD colorectal cancer screening momentum
Reveal MRD growth and pipeline
Oncology business volume and revenue
Revenue
$334.98M
▲ 44.3% YoY Diluted EPS
$-0.90
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Jefferies 2026 Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-02
William Blair 46th Annual Growth Stock Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Guardant Health, Inc. Q1 FY2026 Earnings Call
Confident tone
Screening (Shield) business
Oncology business performance
Reveal MRD product
Revenue
$301.67M
▲ 48.3% YoY Diluted EPS
$-0.85
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-11
Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-19
Guardant Health, Inc. Q4 FY2025 Earnings Call
Confident tone
Shield Screening and Multi-Cancer Detection
MRD and Reveal Product Expansion
Oncology Business and Guardant360 Smart Platform
Revenue
$281.27M*
▲ 39.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-29
Guardant Health, Inc. Q3 FY2025 Earnings Call
Confident tone
Screening / Shield launch
Competition in colorectal cancer screening
Reveal / MRD progress
Revenue
$265.20M
▲ 38.5% YoY Diluted EPS
$-0.74
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-30
Guardant Health, Inc. Q2 FY2025 Earnings Call
Confident tone
Oncology volume and revenue growth
Shield CRC screening commercialization
Reveal MRD progress and reimbursement
Revenue
$232.09M
▲ 30.9% YoY Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-30
Guardant Health, Inc. Q1 FY2025 Earnings Call
Confident tone
Oncology business performance
Shield CRC screening
Reveal MRD progress and reimbursement
Revenue
$203.47M
▲ 20.8% YoY Diluted EPS
$-0.77
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
Guardant Health, Inc. Q4 FY2024 Earnings Call
Confident tone
Therapy Selection Growth and Guardant360 Upgrade
Reveal MRD and CRC Surveillance Coverage
Clinical Evidence and Guidelines
Revenue
$201.81M*
▲ 30.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Guardant Health, Inc. Q3 FY2024 Earnings Call
Confident tone
Precision Oncology / Guardant360 LVT Upgrade
Shield CRC Screening Launch and Reimbursement
Reimbursement and Pricing Tailwinds
Revenue
$191.48M
▲ 33.9% YoY Diluted EPS
$-0.88
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Guardant Health, Inc. Q2 FY2024 Earnings Call
Confident tone
FDA Approval of Shield for CRC Screening
Clinical Volume Growth (G360 and Beyond)
Shield Commercial Launch and Market Opportunity
Revenue
$177.24M
▲ 29.2% YoY Diluted EPS
$-0.84
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Guardant Health, Inc. Q1 FY2024 Earnings Call
Balanced tone
Interest rate environment and rate sensitivity
Capital recycling and distribution policy
Investment pipeline and new construction LIHTC challenges
Revenue
$168.49M
▲ 30.9% YoY Diluted EPS
$-0.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Guardant Health, Inc. Q4 FY2023 Earnings Call
Positive tone
Therapy Selection growth and reimbursement
MRD / Reveal platform
Shield CRC screening / FDA
Revenue
$155.05M*
▲ 22.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Guardant Health, Inc. Q3 FY2023 Earnings Call
Revenue
$143.03M
▲ 21.8% YoY Diluted EPS
$-0.73
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Guardant Health, Inc. Q2 FY2023 Earnings Call
Revenue
$137.15M
▲ 25.7% YoY Diluted EPS
$-0.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Guardant Health, Inc. Q1 FY2023 Earnings Call
Revenue
$128.71M
▲ 33.9% YoY Diluted EPS
$-1.30
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Guardant Health, Inc. Q4 FY2022 Earnings Call
Revenue
$126.89M*
▲ 17.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Guardant Health, Inc. Q3 FY2022 Earnings Call
Revenue
$117.40M
▲ 23.9% YoY Diluted EPS
$-1.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Guardant Health, Inc. Q2 FY2022 Earnings Call
Revenue
$109.14M
▲ 18.5% YoY Diluted EPS
$-2.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Guardant Health, Inc. Q1 FY2022 Earnings Call
Revenue
$96.10M
▲ 22.2% YoY Diluted EPS
$-1.21
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-23
Guardant Health, Inc. Q4 FY2021 Earnings Call
Revenue
$108.11M*
▲ 38% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Guardant Health, Inc. Q3 FY2021 Earnings Call
Revenue
$94.78M
▲ 27.1% YoY Diluted EPS
$-1.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Guardant Health, Inc. Q2 FY2021 Earnings Call
Revenue
$92.10M
▲ 38.8% YoY Diluted EPS
$-0.96
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Guardant Health, Inc. Q1 FY2021 Earnings Call
Revenue
$78.67M
▲ 16.5% YoY Diluted EPS
$-1.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-24
Guardant Health, Inc. Q4 FY2020 Earnings Call
Revenue
$78.32M*
▲ 24.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Guardant Health, Inc. Q3 FY2020 Earnings Call
Revenue
$74.57M
▲ 22.5% YoY Diluted EPS
$-0.78
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Guardant Health, Inc. Q2 FY2020 Earnings Call
Revenue
$66.33M
▲ 22.9% YoY Diluted EPS
$-0.57
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Guardant Health, Inc. Q1 FY2020 Earnings Call
Revenue
$67.51M
▲ 84.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-24
Guardant Health, Inc. Q4 FY2019 Earnings Call
Revenue
$62.90M*
▲ 91.3% YoY
Rev · 7q
Audio
Transcript
Slides
8-K10-K
Showing 1–31 of 31 earnings calls
Key facts
CIK
1576280
CUSIP
40131M109
13F (30d)
219 filings
194 filers
Visit website
Investor relations